HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J

This article was originally published in The Rose Sheet

Executive Summary

Worldwide skin care sales up 7% in third quarter, led by Aveeno brand and recently-introduced Neutrogena Visibly Firm with Active Copper night and eye creams in U.S. and sun care sales abroad, firm says Oct. 16. Copper-containing products debuted in May (1"The Rose Sheet" Feb. 26, p. 4). Johnson's BedTime baby skin care line extensions led an 8% gain in worldwide baby care sales for the period. U.S. consumer sales gained 4.8% to $984 mil., leading a 1.3% increase in worldwide consumer sales to $1.78 bil. Consolidated company sales rose 10.8% to $8.24 bil. in the quarter and net earnings were up 15.6% to $1.55 bil

You may also be interested in...



Neutrogena Visibly Firm Takes Elemental Approach With Active Copper

Neutrogena Visibly Firm Night and Eye creams employ the nutrient copper to restore skin firmness and regain measurably smooth, buoyant skin, the Johnson & Johnson division said at a press event in New York City Feb. 20.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
UsernamePublicRestriction

Register

RS009730

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel